Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIn week 2 of Wegovy you are still on the 0.25mg starting dose, so dramatic weight loss is unlikely this early — but this is the week many people notice their appetite beginning to shift for the first time. Your system is adapting to semaglutide, and the side effects that caught you off guard in week 1 may ease, intensify, or show up late. It is a prescription-only medicine, and everything you experience should be discussed with your prescribing clinician rather than managed alone. Learn more about how Wegovy works if you are still weighing up whether it is right for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: it is Saturday morning, you have just administered your second Wegovy injection, and you are scrolling through forums at 7am wondering whether everything you are feeling is normal. Week 2 tends to feel like a strange in-between, enough has changed to be noticeable, but not enough to feel transformative.
The 0.25mg dose is not a therapeutic weight-loss dose; it exists purely to let your gut and brain adjust to semaglutide before the real titration starts. So if the scales look identical to last week, that is entirely expected. What you are more likely to notice is a subtle shift in your relationship with food: meals feeling satisfying sooner, the mid-afternoon biscuit craving arriving a little quieter, or simply forgetting to think about lunch. Wegovy does take time to build its full effect, and week 2 is still very early days.
Nausea is the side effect patients most commonly report in this second week, particularly in the 12–24 hours after the injection. For many people it is milder than week 1, especially if they have already learned to keep meals smaller and less fatty. Others find it arrives later in the week, almost as a delayed wave. Loose stools, bloating and indigestion also feature regularly. These are part of the typical Wegovy adjustment arc and tend to track downward as your dose stays stable. The NHS medicines page for semaglutide lists the full side-effect profile and is worth bookmarking.
Most gastrointestinal side effects in week 2 are uncomfortable but not dangerous. Nausea, burping, mild constipation and a tender stomach are the body's response to slowed gastric emptying, semaglutide slows the rate at which food leaves your stomach, which is part of how it reduces appetite. Eating bland, low-fat meals in smaller portions, avoiding large gaps between meals, and drinking water steadily across the day (rather than in large quantities at once) all make a genuine difference.
That said, some symptoms do warrant medical attention rather than patience. Severe stomach pain that does not settle (particularly if it spreads toward your back) needs prompt assessment; the MHRA's Drug Safety Update communications have highlighted acute pancreatitis as an infrequent but serious risk with GLP-1 medicines. Signs of significant dehydration from repeated vomiting or diarrhoea also need clinical input quickly. Mild symptoms: manage with lifestyle adjustments and keep your prescriber informed. Severe or persistent ones: act on them the same day.
If you are taking the oral contraceptive pill alongside Wegovy, the slowed gastric emptying in these early weeks is worth knowing about. Current NHS guidance advises adding a barrier method for the first four weeks of tirzepatide treatment, there is no equivalent specific warning for semaglutide, but if you have any doubts, raising it with your prescriber costs nothing. Our FAQs cover common questions around medicines taken alongside Wegovy.
It would be dishonest to promise you will see a meaningful number on the scales by the end of week 2. Some people do, particularly if they have made dietary changes alongside starting treatment. Many do not. Both outcomes are clinically normal.
What the trial evidence tells us is that significant average weight reduction emerges over months, not days. The STEP 1 trial, published in the New England Journal of Medicine, recorded roughly 15% average body-weight loss over 68 weeks at the 2.4mg maintenance dose, and week 2 participants were still on the same 0.25mg starter dose you are on now. Week 5 is generally when titration has begun and things start to feel different; reading ahead to week 5 can help set realistic expectations for the coming month.
Water retention changes, bowel habits shifting, and meals being slightly smaller can all show up on the scales in unpredictable ways in week 2. Tracking weight at the same time, same day, same conditions (rather than daily spot checks) gives a far more honest picture. If you came to Wegovy from another treatment and are comparing progress, our page on stalling on Wegovy covers what genuine plateaus look like versus early-weeks noise.
The habits you build in week 2 tend to set the tone for the whole treatment. Protein at every meal becomes increasingly important as appetite drops, it is easy to eat very little and inadvertently lose muscle rather than fat, which is the opposite of what treatment is designed to support. Staying active, even walking, helps. And if week 1 felt rocky, take heart: for many people week 2 is noticeably more settled.
Think of it a bit like getting a new morning routine started, the first few days feel effortful and odd, and by day ten it has begun to feel ordinary. The pen in the fridge, the injection on the same day each week, the slightly earlier full feeling at dinner: these small rhythms compound into the larger change.
If you are not yet on Wegovy and are still thinking through your options, checking your eligibility with our prescribers is a good next step. Consultations are free, reviewed the same day by a real clinician, and there is no obligation. If you are already on treatment and want to compare what week 2 looked like versus week 1, the week 1 overview is a useful reference point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.